AbbVie's $10.9 billion acquisition of Apogee raises questions about its dividend impact, but the post suggests there is no need for concern.
Finnhub07/20, 08:05 AM
Related assets
Coming up for ABBV
Explore next
Latest ABBV news
FirstSquawk08/20, 09:57 AM
Piper Sandler raised its price target on AbbVie to $303 from $298.
Bloomberg08/17, 06:28 PM
Bloomberg08/03, 04:58 PM